| Literature DB >> 30754716 |
Gloria Narjara Santos da Silva1, Muriel Primon-Barros2, Alexandre José Macedo3, Simone Cristina Baggio Gnoatto4.
Abstract
New medicines for the treatment of bacterial biofilm formation are required. For thisreason, this study shows the in vitro activity of betulinic acid (BA), ursolic acid (UA) and their twentyderivatives against planktonic and biofilm cells (gram-positive bacterial pathogens: Enterococcusfaecalis, <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>). We evaluated the antibiofilm activity(through the crystal violet method), as well as the antibacterial activity via absorbance (OD<sub>600</sub>) atconcentrations of 5, 25 and 100 μM. Likewise, the cytotoxicity of all compounds was evaluated on akidney African green monkey (VERO) cell line at the same concentration, by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) methodology. We verified for the first timewhether different groups at carbon 3 (C-3) of triterpenes may interfere in the antibiofilm activity withminimal or no antibacterial effect. After the screening of 22 compounds at three distinctconcentrations, we found antibiofilm activity for eight distinct derivatives without antibiotic effect.In particular, the derivative 2f, with an isopentanoyl ester at position C-3, was an antibiofilm activityagainst S. aureus without any effect upon mammalian cells.Entities:
Keywords: Ursolic acid; bacterial pathogens; betulinic acid; cytotoxicity; pathogenic biofilms
Mesh:
Substances:
Year: 2019 PMID: 30754716 PMCID: PMC6406419 DOI: 10.3390/biom9020058
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Chemical structure of betulinic acid (BA) and ursolic acid (UA).
Scheme 1Synthesis of BA (Series 1) and UA (Series 2) derivatives: (i) 24h, refluxed, pyridine, succinic anhydride (1g (91%) and 2g (24%)); 1h, room temperature (rt), CH2Cl2, acetic anhydride (1a (98%) and 2a (100%)), butyric anhydride (1b (25%) and 2b (30%)), pentanoic anhydride (1c (50%) and 2c (56%)), caproic anhydride (1d (47%) and 2d (50%)), isobutyric anhydride (1e (62%) and 2e (45%)); isovaleric anhydride (1f (45%) and 2f (40%)), dichloroacetic anhydride (1h (61%) and 2h (60%)) and bis(trifluoroacetic) anhydride (1i (100%) and 2i (100%)). (ii) 3h, rt, Jone’s reagent/acetone, 1j (85%) and 2j (80%).
Figure 2In vitro antibiofilm and antibacterial activity of Staphylococcus aureus: (A) BA and derivatives; (B) UA and derivatives. Results represent mean ± standard deviation of five experiments. * Represents a significant difference in relation to the biofilm formation control (p < 0.01). # Represents a significant difference in relation to the planktonic cells’ viability control (p < 0.01). BA: betulinic acid; UA: ursolic acid.
Figure 3In vitro antibiofilm and antibacterial activity of Staphylococcus epidermidis: (A) BA and derivatives; (B) UA and derivatives. Results represent mean ± standard deviation of five experiments. * Represents significant difference in relation to biofilm formation control (p < 0.01). # Represents significant difference in relation to planktonic cells viability control (p < 0.01).
Figure 4In vitro antibiofilm and antibacterial activity of Enterococcus faecalis: (A) BA and derivatives; (B) UA and derivatives. The results represent the mean ± standard deviation of five experiments. * Represents a significant difference in relation to the biofilm formation control (p < 0.01). # Represents a significant difference in relation to the planktonic cells’ viability control (p < 0.01).
Citotoxity activity of BA and UA and derivatives against VERO cells.
|
| |||||||||
|
|
|
|
|
|
| ||||
|
| 25 ± 3 * | 30 ± 3 * | 40 ± 6* |
| 13 ± 12 * | 32 ± 7 * | 37 ± 4 * | ||
|
| 31 ± 8 * | 35 ± 11 * | 47 ± 12 * |
| 55 ± 30 * | 74 ± 14 | 73 ± 10 * | ||
|
| 30 ± 7 * | 34 ± 11 * | 46 ± 12 * |
| 60 ± 15 * | 76 ± 15 | 90 ± 13 | ||
|
| 27 ± 10 * | 33 ± 16 * | 50 ± 14 * |
| 64 ± 20 * | 92 ± 6 | 68 ± 20 * | ||
|
| 41 ± 20 * | 56 ± 17 * | 66 ± 8 * |
| 55 ± 4 * | 67 ± 7 * | 65 ± 11 * | ||
|
| 29 ± 11 * | 64 ± 13 * | 63 ± 21 * |
| 52 ± 18 * | 94 ± 18 | 100 ± 16 | ||
|
| 58 ± 9 * | 60 ± 5 * | 63 ± 14* |
| 72 ± 26 | 105 ± 10 | 113 ± 32 | ||
|
| 67 ± 8* | 82 ± 17 | 56 ± 4 * |
| 61 ± 15 * | 46 ± 6 * | 52 ± 3 * | ||
|
| 23 ± 5 * | 35 ± 13 * | 92 ± 6 |
| 81 ± 11 | 81 ± 35 | 86 ± 21 | ||
|
| 10 ± 4 * | 72 ± 10 | 61 ± 7 * |
| 4 ± 0 * | 28 ± 5 * | 69 ± 7 * | ||
|
| 36 ± 18 * | 57 ± 10 * | 52 ± 3 * |
| 45 ± 3 * | 87 ± 8 | 64 ± 16 * | ||
|
| |||||||||
|
|
|
| |||||||
| 100 ± 21 | 91 ± 20 | 3 ± 0 * | |||||||
The results represent the mean ± standard deviation of five experiments. * Represents a significant difference in relation to the control (p < 0.01). VERO cells: kidney African green monkey cell.